Clinical Trials
49 trialsNCT00352534 2026-06-03
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Children's Oncology Group
Phase 3 Completed
NCT03213704 2026-06-02
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03210714 2026-06-01
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01575548 2026-05-29
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04739800 2026-05-29
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04320888 2026-05-27
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03317392 2026-05-20
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT04716725 2026-05-15
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT02555189 2026-04-22
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Terminated
NCT03213678 2026-04-21
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT01038778 2026-04-13
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04831138 2025-12-19
Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma
University of Texas Southwestern Medical Center
Phase NA Terminated
NCT05779943 2025-10-27
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
Emory University
Phase 2 Active not recruiting
NCT04936230 2025-08-17
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT05547386 2025-07-18
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 3 Completed
NCT03448458 2025-07-17
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Emory University
Phase 2 Completed
NCT04927663 2025-05-20
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
University of California, San Francisco
Phase 1 Terminated
NCT02989623 2025-04-24
Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
Thomas Jefferson University
Phase NA Completed
NCT04134208 2025-01-16
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 4 Terminated
NCT03707184 2024-11-29
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
University of Utah
Phase 2 Completed
NCT03513952 2024-07-26
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002981 2024-06-03
PET Scan in Treating Patients With Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT03949517 2024-01-30
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford University
Phase 1/2 Completed
NCT03113617 2023-12-12
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
Stanford University
Phase 2 Completed
NCT02624518 2023-04-10
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Stanford University
Phase 2/3 Completed
NCT04179968 2023-03-20
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02678351 2022-03-04
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Stanford University
Phase 2/3 Completed
NCT02673151 2022-01-13
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Stanford University
Phase 2/3 Completed
NCT01812668 2021-08-05
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT01253668 2021-04-13
Brivanib Metastatic Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT02397408 2020-11-19
11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT01967862 2020-09-17
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
City of Hope Medical Center
Phase NA Completed
NCT01599793 2020-03-26
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
Phase 2 Completed
NCT03007719 2020-01-21
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
University of California, San Francisco
Phase 2 Terminated
NCT02830880 2020-01-07
FACBC Prostate Therapy Response
Emory University
Phase 2 Completed
NCT01816048 2019-12-09
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
University of Wisconsin, Madison
Phase 2 Terminated
NCT01502228 2019-03-05
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
Indiana University
Phase NA Terminated
NCT00436956 2018-10-09
AZD2171 to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02488070 2018-03-20
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Stanford University
Phase 1/2 Completed
NCT01792024 2018-03-13
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
University of Chicago
Phase NA Completed
NCT00537056 2017-06-14
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Stanford University
Phase NA Completed
NCT02440308 2017-04-11
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
Stanford University
Phase 2 Completed
NCT01712685 2017-01-11
Imaging Studies of Kidney Cancer Using 18F-VM4-037
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01821105 2016-03-02
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00147238 2012-08-07
A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast
M.D. Anderson Cancer Center
Phase NA Terminated